Skip to main content

Advertisement

SpringerLink
Log in

Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Insulin resistance is a characteristic feature of type 2 diabetes mellitus, obesity, and the metabolic syndrome. Increased intracellular fat content in skeletal muscle and liver associated with insulin resistance has led to the hypothesis that a mitochondrial defect in substrate oxidation exists in disorders of insulin resistance. In vivo measurements of metabolic fluxes through the tricarboxylic acid and oxidative phosphorylation with magnetic resonance spectroscopy have demonstrated multiple defects in mitochondrial function in skeletal muscle. A decrease in mitochondrial density and mitochondrial copy number has been reported in insulin-resistant individuals. However, these findings have not been a consistent observation in all studies. Similarly, an intrinsic functional defect in mitochondrial adenosine triphosphate production synthesis has been reported in some but not all studies. This review summarizes evidence that implicates a defect in mitochondrial oxidative phosphorylation and its relationship to insulin resistance in common metabolic diseases characterized by impaired insulin action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. DeFronzo RA: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997, 50:191–197.

    Article  PubMed  CAS  Google Scholar 

  2. Reaven GM: Banting lecture. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  3. Gami AS, Witt BJ, Howard DE, et al.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403–414.

    Article  PubMed  CAS  Google Scholar 

  4. Groop LC, Bonadonna RC, DelPrato S, et al.: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989, 84:205–213.

    Article  PubMed  CAS  Google Scholar 

  5. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the Pl 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311–320.

    Article  PubMed  CAS  Google Scholar 

  6. Bajaj M, Defronzo RA: Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003, 10:311–323.

    Article  PubMed  Google Scholar 

  7. DeFronzo RA: Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997, 5:117–169.

    Google Scholar 

  8. Suzuki R, Tobe K, Aoyama M, et al.: Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice. J Biol Chem 2004, 279:25039–25049.

    Article  PubMed  CAS  Google Scholar 

  9. Groop LC, Saloranta C, Shank M, et al.: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991, 72:96–107.

    Article  PubMed  CAS  Google Scholar 

  10. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463–478.

    Article  PubMed  CAS  Google Scholar 

  11. Belfort R, Harrison SA, Brown K, et al.: A placebo controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis. N Engl J Med 2006, 355:2297–2307.

    Article  PubMed  CAS  Google Scholar 

  12. Bajaj M, Suraamornkul S, Romanelli A, et al.: Effect of sustained reduction in plasma free fatty acid concentration on intramuscular long chain-fatty acyl-CoAs and insulin action in patients with type 2 diabetes. Diabetes 2005, 54:3148–3153.

    Article  PubMed  CAS  Google Scholar 

  13. Mayerson AB, Hundal RS, Dufour S, et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51:797–802.

    Article  PubMed  CAS  Google Scholar 

  14. Sharma S, Adrogue JV, Golfman L, et al.: Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:692–700.

    Article  CAS  Google Scholar 

  15. Kim JK, Fillmore JJ, Chen Y, et al.: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001, 98:7522–7527.

    Article  PubMed  CAS  Google Scholar 

  16. Houmard JA, Tanner CJ, Yu C, et al.: Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes 2002, 51:2959–2963.

    Article  PubMed  CAS  Google Scholar 

  17. Ellis BA, Poynten A, Lowy AJ, et al.: Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 2000, 279:E554–E560.

    PubMed  CAS  Google Scholar 

  18. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51:2005–2011.

    Article  PubMed  CAS  Google Scholar 

  19. Adams JM 2nd, Pratipanawatr T, Berria R, et al.: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53:25–31.

    Article  PubMed  CAS  Google Scholar 

  20. Morino K, Petersen KF, Dufour S, et al.: Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005, 115:3587–3593.

    Article  PubMed  CAS  Google Scholar 

  21. Griffin ME, Marcucci MJ, Cline GW, et al.: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999, 48:1270–1274.

    Article  PubMed  CAS  Google Scholar 

  22. Dresner A, Laurent D, Marcucci M, et al.: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253–259.

    Article  PubMed  CAS  Google Scholar 

  23. Yu C, Chen Y, Cline GW, et al.: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230–50236.

    Article  PubMed  CAS  Google Scholar 

  24. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA: Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes 2003, 52:1943–1950.

    Article  PubMed  CAS  Google Scholar 

  25. Thompson AL, Cooney GJ: Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000, 49:1761–1764.

    Article  PubMed  CAS  Google Scholar 

  26. Tippett PS, Neet KE: An allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. J Biol Chem 1982, 257:14846–14852.

    Google Scholar 

  27. Wititsuwannakul D, Kim K: Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. J Biol Chem 1977, 252:7812–7817.

    PubMed  CAS  Google Scholar 

  28. Randle PF, Garland PB, Hales CN, Newsholme EA: The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785–789.

    Article  PubMed  CAS  Google Scholar 

  29. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000, 49:677–683.

    Article  PubMed  CAS  Google Scholar 

  30. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999, 277(6 Pt 1):E1130–E1141.

    PubMed  CAS  Google Scholar 

  31. Cha BS, Ciaraldi TP, Park KS, et al.: Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab 2005, 289:E151–E159.

    Article  PubMed  CAS  Google Scholar 

  32. Thyfault JP, Kraus RM, Hickner RC, et al.: Impaired plasma fatty acid oxidation in extremely obese women. Am J Physiol Endocrinol Metab 2004, 287:E1076–E1081.

    Article  PubMed  CAS  Google Scholar 

  33. Kim JY, Hickner RC, Cortright RL, et al.: Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 2000, 279:E1039–E1044.

    PubMed  CAS  Google Scholar 

  34. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 2005, 307:384–387.

    Article  PubMed  CAS  Google Scholar 

  35. Befroy DE, Petersen KF, Dufour S, et al.: Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007, 56:1376–1381.

    Article  PubMed  CAS  Google Scholar 

  36. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664–671.

    Article  PubMed  CAS  Google Scholar 

  37. Szendroedi J, Schmid AI, Chmelik M, et al.: Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 2007, 4:e154.

    Article  PubMed  CAS  Google Scholar 

  38. Petersen KF, Dufour S, Shulman GI: Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005, 2:e233.

    Article  PubMed  CAS  Google Scholar 

  39. Scheuermann-Freestone M, Madsen PL, Manners D, et al.: Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040–3046.

    Article  PubMed  CAS  Google Scholar 

  40. Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, et al.: Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. Diabetologia 2007, 50:113–120.

    Article  PubMed  CAS  Google Scholar 

  41. Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140–1142.

    Article  PubMed  CAS  Google Scholar 

  42. Brehm A, Krssak M, Schmid AI, et al.: Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 2006, 55:136–140.

    Article  PubMed  CAS  Google Scholar 

  43. Ritov VB, Menshikova EV, He J, et al.: Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005, 54:8–14.

    Article  PubMed  CAS  Google Scholar 

  44. Patti ME, Butte AJ, Crunkhorn S, et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466–8471.

    Article  PubMed  CAS  Google Scholar 

  45. Rolo AP, Palmeira CM: Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006, 212:167–178.

    Article  PubMed  CAS  Google Scholar 

  46. Boushel R, Gnaiger E, Schjerling P, et al.: Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 2007, 50:790–796.

    Article  PubMed  CAS  Google Scholar 

  47. Asmann YW, Stump CS, Short KR, et al.: Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes 2006, 55:3309–3319.

    Article  PubMed  CAS  Google Scholar 

  48. Chavez-Velazquez A, Jani R, Abdul-Ghani MA, et al.: Short-term elevation of plasma free fatty acids (FFA) decreases skeletal muscle mitochondrial membrane potential in healthy glucose tolerant subjects. Diabetes 2007, 56(Suppl 1):242A.

    Google Scholar 

  49. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944–2950.

    Article  PubMed  CAS  Google Scholar 

  50. Toledo FG, Watkins S, Kelley DE: Changes induced by physical activity and weight loss in the morphology of intermyofibrillar mitochondria in obese men and women. J Clin Endocrinol Metab 2006, 91:3224–3227.

    Article  PubMed  CAS  Google Scholar 

  51. Abdul-Ghani MA, Jani R, Molina M, et al.: Decreased mitochondrial ATP synthesis in obese non-diabetic subjects. Diabetes 2008, 56(Suppl 1):1456A.

    Google Scholar 

  52. Mogensen M, Sahlin K, Fernstrom M, et al.: Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007, 56:1592–1599.

    Article  PubMed  CAS  Google Scholar 

  53. Goodpaster BH, Katsiaras A, Kelley DE: Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003, 52:2191–2197.

    Article  PubMed  CAS  Google Scholar 

  54. Greco AV, Mingrone G, Giancaterini A, et al.: Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002, 51:144–151.

    Article  PubMed  CAS  Google Scholar 

  55. Jubrias SA, Esselman PC, Price LB, et al.: Large energetic adaptations of elderly muscle to resistance and endurance training. J Appl Physiol 2001, 90:1663–1670.

    Article  PubMed  CAS  Google Scholar 

  56. Holloszy JO, Coyle EF: Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984, 56:831–838.

    PubMed  CAS  Google Scholar 

  57. Chilibeck PD, Syrotuik DG, Bell GJ: The effect of concurrent endurance and strength training on quantitative estimates of subsarcolemmal and intermyofibrillar mitochondria. Int J Sports Med 2002, 23:33–39.

    Article  PubMed  CAS  Google Scholar 

  58. Ostergard T, Andersen JL, Nyholm B, et al.: Impact of exercise training on insulin sensitivity, physical fitness, and muscle oxidative capacity in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2006, 290:E998–E1005.

    Article  PubMed  CAS  Google Scholar 

  59. Menshikova EV, Ritov VB, Toledo FG, et al.: Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab 2005, 288:E818–E825.

    Article  PubMed  CAS  Google Scholar 

  60. Short KR, Vittone JL, Bigelow ML, et al.: Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. Diabetes 2003, 52:1888–1896.

    Article  PubMed  CAS  Google Scholar 

  61. Richardson DK, Kashyap S, Bajaj M, et al.: Lipid infusion induces an inflammatory/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle. J Biol Chem 2005, 280:10290–10297.

    Article  PubMed  CAS  Google Scholar 

  62. Abdul-Ghani MA, Muller F, Liu Y, et al.: Deleterious effect of elevated fatty acid metabolites concentration on skeletal muscle mitochondrial ATP synthesis. Diabetes 2007, 56(Suppl 1):1303A.

    Google Scholar 

  63. Benton CR, Nickerson JG, Lally J, et al.: Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in SS, not IMF, mitochondria. J Biol Chem 2007 Dec 12 (Epub ahead of print).

  64. Lagouge M, Argmann C, Gerhart-Hines Z, et al.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109–1122.

    Article  PubMed  CAS  Google Scholar 

  65. Lim JH, Lee JI, Suh YH, et al.: Mitochondrial dysfunction induces aberrant insulin signalling and glucose utilisation in murine C2C12 myotube cells. Diabetologia 2006, 49:1924–1936.

    Article  PubMed  CAS  Google Scholar 

  66. Brown AE, Elstner M, Yeaman SJ, et al.: Does impaired mitochondrial function affect insulin signaling and action in cultured human skeletal muscle cells? Am J Physiol Endocrinol Metab 2008, 294:E97–E102.

    Article  PubMed  CAS  Google Scholar 

  67. Pospisilik JA, Knauf C, Joza N, et al.: Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 2007, 131:476–491.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA

    Muhammad A. Abdul-Ghani

Authors
  1. Muhammad A. Abdul-Ghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph A. DeFronzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad A. Abdul-Ghani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abdul-Ghani, M.A., DeFronzo, R.A. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 8, 173–178 (2008). https://doi.org/10.1007/s11892-008-0030-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-008-0030-1

Keywords

Search

Navigation